Disclosed are apparatus and methods for blood and other biological fluid purification using a membrane with cell containing vascular channel systems and filtration channel systems. Also disclosed are methods of making the apparatus as well as methods of making membranes.

The present disclosure relates to devices, e.g, extracorporeal blood purification (EBP) devices, which comprise a cartridge or sorbent comprising a cellular membrane derived from a cell. The present disclosure also relates methods for removing or reducing a substance, e.g, an undesirable substance, from a fluid, e.g, a subject’s blood, using the devices or EBP devices.

A method and device treats cancer where blood from a cancer patient passes through an array of passageways within an interior of a chamber. The passageways include wells having porous membrane wall portions that enable a molecular-sized activating agent in a carrier fluid that enhances an immune response to pass through these porous wall portions. Pore size is such to allow the molecular-sized activating agent in the interior of the chamber to enter the wells yet prevents immune cells and cancer cells in the wells to pass through the porous wall portions into the interior of the chamber. Blood is retained in the wells so that it remains in contact with the immune cells and cancer cells for a predetermined period sufficient to enhance an immune response. Then the cells with an enhanced immune response are return to the patient.

Described are devices and methods for use in connection with organ replacement or organ assist therapy in a patient.

The embodiments provide a bioengineered artificial functional liver which is connected to a patient suffering from acute liver failure and would functional like an ectopic liver. The device uses the cells derived from the patient's own body thereby nullifying the chances of self/non-self-recognition and related immune activation and rejection. The extracted liver cells are grown on a customized 3D matrix called as 3D cell cartridge and these cell cartridges individually function as miniature liver assemblies. Multiple such assemblies when working in parallel would rescue the condition of liver failure. A microfluidic chamber is built with the similar network as found in the liver and the chamber has flow circuits for plasma/de-cellularised blood and the flow circuits are lined by a coculture of hepatocytes, endothelial cells and fibroblasts. The array of cells in the chamber serve as a miniature liver and multiple such arrays will be stacked to achieve a significant hepatic function.

The invention resides in an apparatus for treatment of a substance. The apparatus has a substance tube for enabling a substance to be treated to pass in to the substance tube via the substance-inlet and out of the substance tube through the substance-outlet. The apparatus also has a cleaning chamber, wherein the substance tube is configured in fluid communication with the cleaning chamber to enable a substance to diffuse the permeable membrane between the substance tube and the cleaning chamber such that a substance can be substantially cleaned by a cleaner, the substance comprising blood or plasma and the cleaner comprising a cell culture. The substance tube is removably connectable with the cleaning chamber for inter-changeability or serviceability. The apparatus can further comprise a support compartment configured to connect to, or enclosing, the cleaning chamber, which functions to carry a fluid to substantially maintain the functionality of the cleaner.

The present invention relates to the field of bio-artificial liver technology. Particularly, the invention provides an integrated hybrid bio-artificial liver support system that provides the features of artificial liver assist devices with that of bio-artificial liver support systems.

The present invention relates to a device for the treatment of blood comprising a solid phase on which a polypeptide is immobilized which is suitable for the inactivation of free nucleic acids. Suitable polypeptides are, for example, deoxyribonucleases, ribonucleases, DNA methyltransferases or cytosine deaminases. The invention further comprises the use of such devices for the treatment of patients suffering from chronic kidney failure, cancer or lupus erythematosus, as well as methods and systems for the treatment of blood, wherein free nucleic acids are inactivated outside the body.

A bioartificial liver (BAL) based on human induced pluripotent stem cells (iPSCs)-derived hepatocyte-like cells (HLCs) and a multilayer porous bioreactor is provided. The plasma separation/retransfusion loop part includes a blood input pipe, an exhaust pipe spring clamp, a blood input peristaltic pump, a heparin pump, a plasma separation column, a first pressure monitor, and a heater. The cell reactor/plasma component exchange double-loop part includes a plasma input peristaltic pump, and a semipermeable membrane exchange column, a plasma exchange peristaltic pump, a red blood cell (RBC) pool, a membrane lung, a multilayer porous bioreactor, a second pressure monitor, and a third pressure monitor arranged in a 37° C. dedicated incubator. An outlet of the third pressure monitor and a blood cell outlet are connected to an inlet of the first pressure monitor, and then connected to the heater and a blood output pipe in sequence.

Disclosed are apparatus and methods for blood and other biological fluid purification using a membrane with cell containing vascular channel systems and filtration channel systems. Also disclosed are methods of making the apparatus as well as methods of making membranes.